Previous Article | Next Article 
Infection and Immunity, March 2001, p. 1832-1840, Vol. 69, No. 3
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.3.1832-1840.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Inflammation and Clearance of Chlamydia
trachomatis in Enteric and Nonenteric Mucosae
Joseph U.
Igietseme,1,*
John L.
Portis,2 and
Linda L.
Perry2
Department of Microbiology and Immunology,
Morehouse School of Medicine, Atlanta, Georgia
30310,1 and The Laboratory of
Intracellular Parasites, Rocky Mountain Laboratories, National
Institute of Allergy and Infectious Diseases, National Institutes
of Health, Hamilton, Montana 598402
Received 1 August 2000/Returned for modification 31 August
2000/Accepted 6 December 2000
 |
ABSTRACT |
Immunization(s) fostering the induction of genital mucosa-targeted
immune effectors is the goal of vaccines against sexually transmitted
diseases. However, it is uncertain whether vaccine administration
should be based on the current assumptions about the common mucosal
immune system. We investigated the relationship between mucosal sites
of infection, infection-induced inflammation, and immune-mediated
bacterial clearance in mice using the epitheliotropic pathogen
Chlamydia trachomatis. Chlamydial infection of the
conjunctival, pulmonary, or genital mucosae stimulated significant
changes in tissue architecture with dramatic up-regulation of the
vascular addressin, VCAM, a vigorous mixed-cell inflammatory response
with an influx of
4
1+ T cells, and clearance of
bacteria within 30 days. Conversely, intestinal mucosa infection was
physiologically inapparent, with no change in expression of the local
MAdCAM addressin, no VCAM induction, no histologically detectable
inflammation, and no tissue pathology. Microbial clearance was complete
within 60 days in the small intestine but bacterial titers remained at
high levels for at least 8 months in the large intestine. These
findings are compatible with the notion that VCAM plays a functional
role in recruiting cells to inflammatory foci, and its absence from the intestinal mucosa contributes to immunologic homeostasis at that site.
Also, expression of type 1 T cell-mediated immunity to
intracellular Chlamydia may exhibit tissue-specific
variation, with the rate and possibly the mechanism(s) of clearance
differing between enteric and nonenteric mucosae. The implications of
these data for the common mucosal immune system and the delivery of
vaccines against mucosal pathogens are discussed.
 |
INTRODUCTION |
The existence of a mucosal immune
system distinct from that operative at systemic tissue sites was
suggested by the unique ability of mucosal epithelial cells to
elaborate secretory IgA, a function dependent upon plasma cells and
epithelial cell specializations (27). The revelation that
antigens introduced via the intestinal mucosa elicited sIgA responses
at distant as well as local mucosal sites suggested a functional
linkage between these epithelialized tissues to form a common mucosal
immune system against mucosal pathogens (26). Analyses of
lymphocyte trafficking patterns supported this concept in that
mucosally derived B lymphoblasts homed preferentially to mucosal and
not peripheral lymph nodes (23). Subsequent definition of
MAdCAM as a mucosal addressin expressed constitutively by vascular
endothelia of the mesenteric lymph nodes and intestinal lamina propria,
and of
4
7 as the relevant lymphocyte receptor, provided a
molecular basis for a functionally distinct mucosal lymphocyte
trafficking system (2, 42). Conversely, lymphocyte homing
to peripheral lymph nodes was attributed to the interaction of
L-selectin with the peripheral lymph node addressin, PNAd,
and trafficking to systemic sites of inflammation was attributed to
binding of
4
1+ lymphocytes to the inducible vascular
cell adhesion molecule, VCAM (4, 40).
The relative failure of parenteral immunization schemes to induce a
common mucosal sIgA response (17, 22, 24, 32) indicated
that access to the mucosal immune system may be restricted. Indeed,
while intestinal priming stimulated widespread sIgA production, immunization at nonintestinal mucosae drove only local or regional sIgA
responses and parenteral immunization schemes provided no mucosal
response (17, 22, 24, 32). Based upon these differential immune patterns, compartmentalization of inductive and effector sites
within the common mucosal immune system was theorized (28, 49). Besides, current strategies for delivery of vaccines
against mucosal pathogens rely heavily upon the theories and clinical implications of such a system, even though comparable data on the
mucosal homing properties of T cells are lacking.
The present studies utilized the obligate intracellular pathogen
Chlamydia trachomatis to investigate the cellular and
molecular basis for expression of immunity within distinct mucosal
tissues. The tropism of this bacterium for mucosal epithelial cells and dependence upon type 1 T cell-mediated immunity for clearance (30, 37, 48) provided an ideal system to dissect the
nature of T-cell reactivity at intestinal versus nonintestinal mucosae. Using a murine model system, it was reported previously that not all
routes of immunization against infection with Chlamydia lead to the establishment of protective immunity (11). However,
all immunization routes leading to protection caused the induction of a
high intensity of specific Th1 cells in the genital mucosa (11). Other studies revealed that chlamydial infection
enhanced VCAM expression in the female reproductive tract and
stimulated an influx of
4
7+,
4
1+ T
cells and
4
7+,
4
1
B cells
(13, 38). This contrasted with findings for the intestine, where constitutive expression of MAdCAM was unchanged by infection, VCAM was not induced, and resident T cells were of the
4
1
phenotype (38). To determine which
of these profiles was most representative of mucosal tissues in
general, our studies were extended to two additional mucosae
susceptible to chlamydial infection, specifically to those of the eye
and lung. Results indicated that the conjunctival and pulmonary mucosae
were both characterized by infection-induced expression of VCAM but not
MAdCAM and by
4
1+ inflammatory T cells, in
keeping with the profile identified at the genital mucosa. The
functional expression of T cell-mediated immunity was also similar at
the conjunctival, pulmonary, and genital mucosae in that
Chlamydia was cleared within 30 days of infection. In
contrast, chlamydial clearance was delayed or absent in the small and
large intestine, respectively. These findings have implications for the
differential expression of T- versus B-cell immunity within the common
mucosal immune system and for the delivery of vaccines against mucosal pathogens.
 |
MATERIALS AND METHODS |
Abbreviations.
The following abbreviations are used in this
paper: FACS, fluorescence-activated cell sorting; ICAMs, intercellular
adhesion molecules; IFU, inclusion-forming units; IgA, immunoglobulin
A; MAbs, monoclonal antibodies; MAdCAM, mucosal cellular
adhesion molecule; MoPn, mouse pneumonitis; PBS, phosphate-buffered
saline; sIgA, secretory IgA; STD, sexually transmitted disease; VCAM, vascular cell adhesion molecule.
Chlamydia stocks and antigens.
Stocks of the C. trachomatis agent of MoPn used to infect mice were prepared by
propagating elementary bodies in McCoy cells, as previously described
(43). Stocks were titered by infecting McCoy cells with
varying dilutions of elementary bodies, and the infectious titer was
expressed as IFU per milliliter.
Animals, infection protocols, and chlamydial isolation.
Female C57BL/6 mice, 5 to 8 weeks old, were obtained from The Jackson
Laboratory, Bar Harbor, Maine. All animals were provided with food and
water ad libitum and were maintained in laminar flow racks under
pathogen-free conditions and 12-h light/dark cycles. Mice were infected
intranasally, conjunctivally, vaginally, or orally with 1.0 to 1.5 × 103 IFU of MoPn per mouse in a volume of 30 µl of PBS
while under methoxyflurane anesthesia (38). Clearance of
chlamydial infections was monitored by enumeration of IFU per gram of
minced tissue on susceptible HeLa cell monolayers using indirect
immunofluorescence for the major outer membrane protein
(30).
Immunohistochemistry.
Tissues collected from infected mice
were mounted in OCT medium (Miles Inc., Elkhart, Ind.), frozen in
liquid nitrogen, and stored at
80°C. Tissues were cut into 5-µm
sections on a cryostat microtome, transferred to slides, air dried, and
fixed in 4°C acetone for 30 min. After washing in PBS, tissues were
stained with primary rat MAbs recognizing murine ICAM-1 (CD54, clone
YN1/1.7.4; ATCC, Rockville, Md.), VCAM-1 (CD106, clone M/K2.7; ATCC),
or MadCAM-1 (clone MECA-367; PharMingen, San Diego, Calif.), washed in
PBS, and developed using mouse-Ig-absorbed tetramethyl
rhodamine-conjugated goat anti-rat Ig (Southern Biotechnology
Associates, Birmingham, Ala.), as previously described
(38). Slides were taken with Nikon Microphot Provia 400 daylight film. Images were digitalized using a Polaroid SprintScan
35-mm slide scanner, and figures were assembled in gray scale without
further manipulation using Adobe Photoshop, version 4.0.
Assessment of inflammation.
Tissues were collected from at
least three mice per group at 10 to 225 days after infection and fixed
in 10% buffered formalin. Inflammation in coded samples was evaluated
by an independent laboratory (Histopath of America, Millersville, Md.).
FACS analysis.
At the indicated time periods after
infection, lymphocytes were collected by collagenase disruption of
infected tissues as previously described (38). Single cell
preparations from the indicated organs and tissues were costained with
fluorochrome-labeled MAbs directed against T cells (CD3), B cells
(B220), and selected integrin and adhesion markers (PharMingen) and
were analyzed by flow cytometry as previously described
(38) on a FACScan flow cytometer (Becton Dickinson,
Sunnyvale, Calif.). Controls were stained with isotype-matched
irrelevant antibodies. Fluorochrome-conjugated, mouse-reactive MAbs
used to stain isolated lymphocytes were as follows: CD3
(clone
145-2C11), CD11a (integrin
L chain, clone 2D7), CD18 (integrin
2
chain, clone C71/16), CD29 (integrin
1 chain, clone Ha2-5), CD44
(clone IM7), CD49a (integrin
1 chain, clone Ha31/8), CD49d (integrin
4 chain, clone R1-2), CD62L (L-selectin, clone MEL-14),
CD103 (integrin
E chain), and integrin
7 chain (clone M293).
Binding of biotinylated MAbs was detected with streptavidin-RED613 (Life Technologies, Grand Island, N.Y.). Results are expressed as the
percentage of positively stained cells in each cell preparation and are
representative of data obtained in two to four separate experiments.
 |
RESULTS |
Integrin profiles of T and B lymphocytes recovered from
Chlamydia-infected mucosae.
Infections of the
conjunctival, pulmonary, genital, or intestinal mucosae were
established by ocular, intranasal, intravaginal, or oral delivery of
C. trachomatis, respectively. Ten to twelve days later,
infiltrating lymphocytes recovered by enzymatic digestion of infected
tissues and cells were analyzed by flow cytometry for expression of
integrins and other adhesion molecules that contribute to site-specific
lymphocyte homing. Most lymphocytes from all sites expressed the
L
2 integrin (i.e., lymphocyte function antigen-1) that
serves as a receptor for the ICAMs, a related set of immunoglobulin
superfamily glycoproteins expressed on endothelial cells as well
as on macrophages, lymphocytes, and other cell types (40)
(Fig. 1 and 2). A
majority of lymphocytes from all sites also expressed the
7
integrins
4
7 and/or
E
7, which mediate binding to the
mucosal vascular ligand, MAdCAM, and the epithelial ligand, E-cadherin (7), respectively. This suggested that
immunization via these routes is likely to generate
lymphocytes capable of homing to other mucosal sites that express
MadCAM. However, while expression of
7 integrins was consistently
highest on intestinally derived cells, the relative expression of
1
integrins most reliably distinguished the lymphocyte tissue
source. T cells but not B cells from the conjunctival, pulmonary, and
genital mucosae expressed high levels of the
1 integrin chain
that complexes with
1 or
4 to form receptors for type IV collagen
or fibronectin, respectively (Fig. 1 and 2). In contrast,
1
integrins were only weakly expressed by intestinal T cells. T cells but
not B cells from all sites also uniformly expressed the Pgp-1 isoform
of CD44 (Fig. 3), a hyaluronate receptor
required for migration into inflammatory foci (8).
L-Selectin, a carbohydrate receptor expressed at high
levels on lymph node cells that encounter the peripheral lymph node
addressin (40), was expressed on less than 50% of T or B
lymphocytes derived from the pulmonary, genital, and intestinal mucosae
(Fig. 3). Collectively, these integrin profiles distinguished lymphocyte subpopulations from intestinal and nonintestinal sources in
that CD44 connective tissue receptors were up-regulated only on T cells
and
1 receptors only on T cells from nonintestinal Chlamydia-infected mucosae.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 1.
Integrin profiles of T and B lymphocytes recovered from
Chlamydia-infected pulmonary, conjunctival, genital, and
intestinal mucosae. Four groups of female C57BL/6 mice were each
infected intranasally, conjunctivally, vaginally, or orally with 1.0 to
1.5 × 103 IFU of the MoPn agent. Lymphocytes
collected by collagenase disruption of infected tissues were costained
with a panel of MAbs recognizing murine CD3, B220, or the indicated
integrin chains and were analyzed by flow cytometry as previously
described (10, 35). Data summarized from 10 separate
experiments represent the mean percent positive T cells (top panel) or
B cells (lower panel) for each integrin marker as determined by
quadrant analyses of FACS plots. Note the heightened expression of 1
integrins on T but not B lymphocytes from nonintestinal mucosae.
|
|

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 2.
FACS plots of integrin chains expressed by T and B
lymphocytes infiltrating Chlamydia-infected pulmonary
mucosae. Graphic representation of the relative fluorescent intensity
of staining for the various integrin markers and the proportion of
cells falling within each quadrant, for cells gated for CD3 or B220
expression. Markers such as 4, 1, and 7 are expressed on all
cells at variable levels. For example, note the differential induction
of 1 integrin chains on T versus B lymphocytes.
|
|

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 3.
Nonintegrin adhesion molecules expressed by T and B
cells infiltrating mucosal sites of Chlamydia infection.
CD44 is up-regulated on T but not B cells from the pulmonary, genital,
and intestinal mucosae, as determined by flow cytometric analyses of
cells recovered from collagenase-digested tissues (see legend to Fig.
1). L-Selectin was variably expressed on cells from either
subset. L-Selectin was detected using the CD62L-specific
MAb clone MEL-14, and CD44 was detected using MAb clone IM7, which
recognizes the Pgp-1 isoform (PharMingen).
|
|
Profiles of vascular addressin expression in
Chlamydia-infected mucosae.
To evaluate the
relationship between the profile of lymphocyte integrins detected and
the expression of corresponding vascular addressins at mucosal sites,
immunohistochemical studies were conducted and site-specific expression
of specific vascular addressins were compared in intestinal and
nonintestinal mucosae. Immunofluorescent staining of frozen tissue
sections revealed expression of MAdCAM on multiple small
vessels within the lamina propria of the small intestine, as expected
(42) (Fig. 4). VCAM-1 was
not detected in the small or large intestine of infected mice, similar
to findings in other models of intestinal disease (3). In
contrast, endothelial cells at infected conjunctival, pulmonary, and
genital mucosae displayed the reciprocal profile with vascular
expression of VCAM but low MAdCAM (Fig. 4). ICAM-1 was
expressed at high levels by endothelial as well as stromal cells in all
tissues examined, in keeping with the pervasive distribution of the
complementary
L
2 lymphocyte receptor (Fig. 1 and data not shown).
Overall, it appeared that induction of ICAM-1 was a common tissue
response to chlamydial infection but that up-regulation of VCAM-1 was
restricted to mucosae outside the gastrointestinal tract
(38). MAdCAM, on the other hand, was detected
mainly in intestinal tissues where expression was constitutive
(42) and apparently unaffected by infection.

View larger version (128K):
[in this window]
[in a new window]
|
FIG. 4.
Expression of VCAM and MAdCAM at mucosal sites
of Chlamydia infection. Tissues collected from mice infected
as described in Table 1 were mounted in OCT, frozen in liquid nitrogen,
and stored at 80°C. Five-micrometer sections were cut on a cryostat
microtome, transferred to slides, air dried, and fixed in 4°C acetone
for 30 min. Tissues were stained with primary rat MAbs recognizing
murine ICAM-1, VCAM-1, or MAdCAM-1, washed in PBS, and
developed using mouse-Ig-absorbed tetramethylrhodamine-conjugated goat
anti-rat Ig as previously described (10, 35). Slides were
viewed with a Nikon Microphot SA epifluorescence microscope, and
photomicrographs were taken with Fujichrome Provia 400 daylight film.
Images were digitized using a Polaroid SprintScan 35-mm slide scanner,
and figures were assembled in gray scale without further manipulation
using Adobe Photoshop, version 4.0. Although the intense
autofluorescence of murine conjunctival tissues precluded satisfactory
photographic documentation, the staining profile was similar to that of
other nonintestinal mucosae in that VCAM-1 but not MAdCAM-1
was detected. Arrows indicate vascular structures in each tissue.
|
|
Inflammation and clearance of Chlamydia from infected
mucosal tissues.
Detection of consistent differences in the
profile of homing ligands and receptors expressed at intestinal versus
nonintestinal mucosae prompted a comparison of functional parameters of
immunity at these same sites. Infections of the pulmonary or genital
mucosae with 1.0 to 1.5 × 103 IFU of C. trachomatis were cleared within 4 weeks with peak recoveries of 5 to 10 × 106 organisms per gram of tissue (Table
1). Conjunctival infections were cleared
more rapidly with minimal chlamydial shedding over a 7- to 10-day
period (data not shown), which accords with previous reports (44,
47). Infections of the small intestine were cleared more slowly,
requiring up to 2 months before organisms could no longer be cultured
from tissues. Surprisingly, infections of the large intestine were
maintained for the entire 8-month observation period at a fairly
constant level of 5 × 105 bacteria per gram of
tissue. Similar results were achieved when animals were inoculated
orally with 102 to 108 IFU of C. trachomatis, suggesting a replication plateau at that level (data
not shown). The persistence of Chlamydia in the large intestine precluded attempts to measure expression of acquired immunity
in the small intestine, since chronic Chlamydia shedding from colonic epithelia could potentially colonize adjacent cells of the
ileum and, possibly, the jejunum to confound results. Acquired immunity
to chlamydial infection has been documented in the genital (5,
6) and pulmonary (51) mucosae and appears to exist at the conjunctival mucosa as well (46).
Chlamydial infection of the conjunctival, pulmonary, or genital mucosa
has been shown to induce a vigorous host inflammatory response,
characterized by a mixed cellular infiltrate comprised of neutrophils
and lymphoid cells (34, 36). Inflammatory responses in the
Chlamydia-infected intestine were monitored by histological analysis of normal versus infected tissue samples collected at several
time points throughout the infection period (days 3, 10, 20, 60, 180, and 240). No differences were detected between infected and uninfected
samples of small or large intestinal tissues (Fig. 5). Densities of intraepithelial and
lamina propria lymphocytes were indistinguishable, consistent with the
failure of infection to induce an increase in the number of lymphocytes
recoverable from this site (38). Neither was there any
evidence for intestinal tissue pathology, hyperplasia of the Peyer's
patches being the only apparent response to infection (data not shown).
The development of hydrosalpinx and infertility is a common result of
genital chlamydia infections (36), while pulmonary
pathology is largely related to inflammation and alveolar congestion
(50). Overall, the response of the intestinal tissues to
chlamydial infection appears to be quite distinct from that of other
mucosal tissues.

View larger version (108K):
[in this window]
[in a new window]
|
FIG. 5.
Inflammatory responses within
Chlamydia-infected pulmonary, genital, and intestinal
mucosae. Mice were infected as described in Fig. 1, and tissues were
collected 10 to 18 days later. Mixed infiltrates comprised of
neutrophils and mononuclear cells were present within infected (bottom
row) but not in normal (top row) pulmonary, genital, and conjunctival
(not shown) mucosae, whereas no evidence of inflammation was detected
within infected intestinal mucosa.
|
|
 |
DISCUSSION |
Targeting the host immune response to specific mucosal tissues is
critical to the control of Chlamydia, human immunodeficiency virus, and other pathogens that utilize a mucosal route of entry. Since
definition of the common mucosal immune system was based essentially on
the trafficking pattern of mucosal B cells and the distribution of
mucosal sIgA antibody responses, it is uncertain whether those findings
are directly relevant to mucosal T-cell function. This is particularly
relevant since several mucosally encountered pathogens, including
C. trachomatis, are controlled by T cell-mediated immunity
requiring the induction and recruitment of Th1 cells into a specific
mucosa microenvironment. To address this issue, the ability of C. trachomatis to induce expression of vascular addressins,
inflammation, and immune-mediated clearance was compared for four
distinct mucosal tissues. Collectively, the results reveal two distinct
profiles of reactivity to mucosal Chlamydia infections. In
the mucosae of the eye, lung, and genital tract, infection stimulated
an
4
1-VCAM T-cell homing pathway, vigorous inflammation, and
reasonably efficient bacterial clearance. Within the intestine, T cells
homed via an
4
7-MAdCAM pathway and bacteria persisted
for longer periods yet no host inflammatory response was evoked. It
would therefore appear that immunological events defined for the
intestinal mucosa are not broadly applicable to all mucosal tissues, at
least in the system under study.
The absence of infection-induced inflammation in the intestinal mucosa
was unexpected given the exquisite sensitivity of other mucosal tissues
to the presence of Chlamydia. Within the genital tract,
inflammation was induced even during infections with nonmurine isolates
of Chlamydia (peak recoveries of less than 104
IFU), yet infection of the intestine with up to 108 IFU of
a murine strain failed to stimulate a local tissue response (data not
shown). It seems likely that suppression of infection-induced inflammation and the persistence of viable Chlamydia in
intestinal epithelial cells are consequences of the tissue-specific
evolutionary adaptations that developed at this site to dampen T-cell
responsiveness against commensal bacteria and food antigens (1,
14). The implication of this finding is that oral immunization
may not be suitable for inducting immune T cells targeted to the
genital mucosa.
Expression of VCAM at sites of mucosal inflammation and of
MAdCAM at noninflammatory locations suggests that vascular
addressins may serve a functional role in lymphocyte trafficking. In
this respect, it is conceivable that VCAM-mediated selection of an
4
1-rich lymphocyte population that has dual binding specificity for extracellular matrix proteins (fibronectin) provides a pool of
T cells capable of interacting with the surrounding tissue during
migration to sites of epithelial infection or during the tissue
remodeling that probably occurs during infection and recovery. On the
other hand, MAdCAM-based selection of an
4
7-rich
lymphocyte population with diminished expression of the
1 family of
connective tissue receptors may contribute directly or indirectly to
the down-regulation of T-cell reactivity within the highly complex intestinal immune system. Identification of these vascular ligands as
direct or indirect regulators of immune function rather than as markers
of systemic versus mucosal tissues requires further experimental
verification. However, this interpretation is consistent with the
different profiles of inflammatory reactivity at MAdCAM- versus VCAM-rich mucosae and the broad tissue distribution of both
ligands, which encompasses mucosal as well as systemic sites (4,
9, 16, 40, 41).
Differential expression of VCAM- and MAdCAM-based trafficking
pathways at enteric and nonenteric mucosae may alter current concepts
of the common mucosal immune system and the practical options for
delivery of vaccines against mucosal pathogens. Trafficking of
intestinally primed
4
7+ T and B lymphocytes is
theoretically unrestricted since the
4
7 integrin carries binding
sites for MAdCAM as well as the related VCAM molecule
(15, 52), allowing homing of intestinal lymphocytes to any
tissue or organ that expresses at least one of these ligands. The
tendency of intestinally primed mice to generate significant serum IgG
titers may be one reflection of this broad trafficking potential
(12, 18, 20, 25, 45). In contrast, parenterally primed T
cells expressing high levels of the
4
1 integrin may be restricted
to tissues expressing the VCAM ligand, thus ensuring the absence of
undesirable inflammatory responses within the VCAM-negative mucosa of the intestine. The overall result of the proposed
trafficking schemes is the generation of systemic as well as
mucosal T and B cell immune responses to mucosally introduced
pathogens, with the intestine being excluded from the recirculation
pathway of parenterally primed, VCAM-restricted T cells. The
generation of mucosal as well as systemic immune responses to mucosal
pathogens is probably one mechanism utilized by the immune system to
deter potential dissemination of these organisms to deeper tissues.
The reciprocal situation that involves the development of
mucosal immune responses following systemic priming
requires further evaluation. It has been demonstrated repeatedly
that sIgA responses do not develop following systemic
immunization (17, 22, 24, 32), consistent with the
irrelevance of a surface antibody response to defense against a
systemic pathogen. Unlike the B cell, however, there is no apparent
specialization of T-cell function in mucosal tissues, at least at
VCAM-rich mucosae. Data are compatible with the notion that
conventional T cells utilizing an
4
1-VCAM homing pathway are
capable of migrating into systemic or mucosal sites of inflammation
(intestine excluded), suggesting that there may be fewer barriers to
parenteral induction of a mucosal T-cell response than were predicted
by measures of mucosal antibody induction. Indeed, available evidence
suggests that systemic immunization can induce protective T
cell-mediated immunity against several mucosal pathogens (17, 19,
29, 33, 53).
Admittedly, division of host tissues into VCAM-,
MAdCAM-, and peripheral lymph node addressin-expressing
sites is an oversimplification of a complex set of interactions that
ultimately result in site-specific lymphocyte homing. No account has
been made for the existence of vascular addressin splice variants
(21, 39), the extensive promiscuity of relevant
receptor-ligand interactions (15, 31, 52), or the
potential existence of undiscovered adhesion molecules that could
contribute to mucosal versus systemic tissue trafficking. Nevertheless,
it appears that expression of the MAdCAM addressin in mucosal
tissues may be limited, which would suggest that it may not serve as a
vascular marker for a common mucosal immune system. It is equally
apparent that T lymphocytes trafficking to nonintestinal sites of
mucosal infection utilize homing signals that are shared at systemic
sites of inflammation. Thus, the rules established for B-cell
trafficking within the common mucosal immune system may not be strictly
applicable to T cells migrating to mucosal sites of bacterial infection.
 |
ACKNOWLEDGMENTS |
This study was partially supported by institutional research
support from PHS grants AI41231 and RR03034 from the National Institutes of Health.
Special appreciation is extended to Scott Hughes for expert technical
assistance, Bob Evans for graphic illustrations, and Mark Jutila for
exchange of information and advice.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, Morehouse School of Medicine, 720 Westview Dr., S.W., Atlanta, GA 30310. Phone: (404) 752-1596. Fax: (404) 752-1179. E-mail: igietsj{at}msm.edu.
Editor:
J. D. Clements
 |
REFERENCES |
| 1.
|
Abreu-Martin, M. T., and S. R. Targan.
1996.
Regulation of immune response of the intestinal mucosa.
Crit. Rev. Immunol.
16:277-309[Medline].
|
| 2.
|
Berlin, C.,
E. L. Berg,
M. J. Briskin,
D. P. Andrew,
P. J. Kilshaw,
B. Holzmann,
I. L. Weissman,
A. Hamann, and E. C. Butcher.
1993.
Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1.
Cell
74:185-195[CrossRef][Medline].
|
| 3.
|
Briskin, M.,
D. Winsor-Hines,
A. Shyjan,
N. Cochran,
S. Bloom,
J. Wilson,
L. M. McEvoy,
E. C. Butcher,
N. Kassam,
C. R. Mackay,
W. Newman, and D. J. Ringler.
1997.
Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue.
Am. J. Pathol.
151:97-110[Abstract].
|
| 4.
|
Butcher, E. C., and L. J. Picker.
1996.
Lymphocyte homing and homeostasis.
Science
272:60-66[Abstract].
|
| 5.
|
Byrne, G. I.
1989.
The host cell, host immune responses, and the intracellular growth of chlamydia, p. 35-49.
In
J. W. Moulder (ed.), Intracellular parasitism. CRC Press, Inc., Boca Raton, Fla.
|
| 6.
|
Byrne, G. I.
1998.
Immunity to Chlamydia, p. 365-374.
In
R. S. Stephens, G. I. Byrne, G. Christiansen, I. N. Clarke, J. T. Grayston, R. G. Rank, G. L. Ridgway, P. Saikku, J. Schachter, and W. E. Stamm (ed.), Chlamydial infections, 1998. University of California, Berkeley, Calif.
|
| 7.
|
Cepek, K. L.,
S. K. Shaw,
C. M. Parker,
G. J. Russell,
J. S. Morrow,
D. L. Rimm, and M. B. Brenner.
1994.
Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin.
Nature
372:190-193[CrossRef][Medline].
|
| 8.
|
DeGrendele, H. C.,
P. Estess, and M. H. Siegelman.
1997.
Requirement for CD44 in activated T cell extravasation into an inflammatory site.
Science
278:672-675[Abstract/Free Full Text].
|
| 9.
|
Hanninen, A.,
C. Taylor,
P. R. Streeter,
L. S. Stark,
J. M. Sarte,
J. A. Shizuru,
O. Simell, and S. A. Michie.
1993.
Vascular addressins are induced on islet vessels during insulitis in nonobese diabetic mice and are involved in lymphoid cell binding to islet endothelium.
J. Clin. Investig.
92:2209-2215.
|
| 10.
|
Harrison, H. R.,
S. M. Lee, and D. O. Lucas.
1982.
Chlamydia trachomatis pneumonitis in the C57BL/KsJ mouse: pathologic and immunologic features.
J. Lab. Clin. Med.
100:953-962[Medline].
|
| 11.
|
Igietseme, J. U.,
I. M. Uriri,
S. N. Kumar,
G. A. Ananaba,
O. O. Ojior,
I. A. Momodu,
D. H. Candal, and C. M. Black.
1998.
Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice.
Infect. Immun.
66:4030-4035[Abstract/Free Full Text].
|
| 12.
|
Jain, S. L.,
K. S. Barone,
M. P. Flanagan, and J. G. Michael.
1996.
Activation patterns of murine B cells after oral administration of an encapsulated soluble antigen.
Vaccine
14:42-48[CrossRef][Medline].
|
| 13.
|
Kelly, K. A., and R. G. Rank.
1997.
Identification of homing receptors that mediate the recruitment of CD4 T cells to the genital tract following intravaginal infection with Chlamydia trachomatis.
Infect. Immun.
65:5198-5208[Abstract].
|
| 14.
|
Khoo, U. Y.,
I. E. Proctor, and A. J. Macpherson.
1997.
CD4+ T cell down-regulation in human intestinal mucosa: evidence for intestinal tolerance to luminal antigens.
J. Immunol.
158:3626-3634[Abstract].
|
| 15.
|
Kilger, G.,
J. Clements, and B. Holzmann.
1997.
Amino acid residues required for binding of vascular cell adhesion molecule-1 to integrin alpha 4 beta 7.
Int. Immunol.
9:219-226[Abstract/Free Full Text].
|
| 16.
|
Kraal, G.,
K. Schornagel,
P. R. Streeter,
B. Holzmann, and E. C. Butcher.
1995.
Expression of the mucosal vascular addressin, MAdCAM-1, on sinus-lining cells in the spleen.
Am. J. Pathol.
147:763-771[Abstract].
|
| 17.
|
Kuklin, N.,
M. Daheshia,
K. Karem,
E. Manickan, and B. T. Rouse.
1997.
Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization.
J. Virol.
71:3138-3145[Abstract].
|
| 18.
|
Kuklin, N. A.,
M. Daheshia,
P. C. Marconi,
D. M. Krisky,
R. J. Rouse,
J. C. Glorioso,
E. Manican, and B. T. Rouse.
1998.
Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines.
Virology
240:245-253[CrossRef][Medline].
|
| 19.
|
Langermann, S.,
S. Palaszynski,
M. Barnhart,
G. Auguste,
J. S. Pinkner,
J. Burlein,
P. Barren,
S. Koenig,
S. Leath,
C. H. Jones, and S. J. Hultgren.
1997.
Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination.
Science
276:607-611[Abstract/Free Full Text].
|
| 20.
|
Langermann, S.,
S. Palaszynski,
A. Sadziene,
C. K. Stover, and S. Koenig.
1994.
Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi.
Nature
372:552-555[CrossRef][Medline].
|
| 21.
|
Leung, E.,
J. Greene,
J. Ni,
L. G. Raymond,
K. Lehnert,
R. Langley, and G. W. Krissansen.
1996.
Cloning of the mucosal addressin MAdCAM-1 from human brain: identification of novel alternatively spliced transcripts.
Immunol. Cell Biol.
74:490-496[Medline].
|
| 22.
|
Lue, C.,
A. van den Wall Bake,
S. J. Prince,
B. A. Julian,
M. L. Tseng,
J. Radl,
C. O. Elson, and J. Mestecky.
1994.
Intraperitoneal immunization of human subjects with tetanus toxoid induces specific antibody-secreting cells in the peritoneal cavity and in the circulation, but fails to elicit a secretory IgA response.
Clin. Exp. Immunol.
96:356-363[Medline].
|
| 23.
|
McDermott, M. R., and J. Bienenstock.
1979.
Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues.
J. Immunol.
122:1892-1898[Abstract/Free Full Text].
|
| 24.
|
McGhee, J. R.,
J. Mestecky,
M. T. Dertzbaugh,
J. H. Eldridge,
M. Hirasawa, and H. Kiyono.
1992.
The mucosal immune system: from fundamental concepts to vaccine development.
Vaccine
10:75-88[CrossRef][Medline].
|
| 25.
|
Medaglini, D.,
G. Pozzi,
T. P. King, and V. A. Fischetti.
1995.
Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization.
Proc. Natl. Acad. Sci. USA
92:6868-6872[Abstract/Free Full Text].
|
| 26.
|
Mestecky, J.
1987.
The common mucosal immune system and current strategies for induction of immune responses in external secretions.
J. Clin. Immunol.
7:265-276[CrossRef][Medline].
|
| 27.
|
Mestecky, J., and J. R. McGhee.
1987.
Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response.
Adv. Immunol.
40:153-245[Medline].
|
| 28.
|
Mestecky, J.,
Z. Moldoveanu,
M. Novak, and R. W. Compans.
1994.
Mucosal immunity and strategies for novel microbial vaccines.
Acta Paediatr. J.
36:537-544.
|
| 29.
|
Morrison, L. A.,
X. J. Da Costa, and D. M. Knipe.
1998.
Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge.
Virology
243:178-187[CrossRef][Medline].
|
| 30.
|
Morrison, R. P.,
K. Feilzer, and D. B. Tumas.
1995.
Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection.
Infect. Immun.
63:4661-4668[Abstract].
|
| 31.
|
Newham, P.,
S. E. Craig,
K. Clark,
A. P. Mould, and M. J. Humphries.
1998.
Analysis of ligand-induced and ligand-attenuated epitopes on the leukocyte integrin alpha4betal: VCAM-1, mucosal addressin cell adhesion molecule-1, and fibronectin induce distinct conformational changes.
J. Immunol.
160:4508-4517[Abstract/Free Full Text].
|
| 32.
|
Ogra, P. L., and S. S. Ogra.
1973.
Local antibody response to poliovaccine in the human female genital tract.
J. Immunol.
110:1307-1311[Abstract/Free Full Text].
|
| 33.
|
Pal, S.,
I. Theodor,
E. M. Peterson, and L. M. de la Maza.
1997.
Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge.
Infect. Immun.
65:3361-3369[Abstract].
|
| 34.
|
Patton, D. L.
1985.
Immunopathology and histopathology of experimental chlamydial salpingitis.
Rev. Infect. Dis.
7:746-753[Medline].
|
| 35.
|
Patton, D. L.,
D. V. Landers, and J. Schachter.
1989.
Experimental Chlamydia trachomatis salpingitis in mice: initial studies on the characterization of the leukocyte response to chlamydial infection.
J. Infect. Dis.
159:1105-1110[Medline].
|
| 36.
|
Patton, D. L., and R. G. Rank.
1992.
Animal models for the study of pelvic inflammatory disease, p. 85-111.
In
T. C. Quinn (ed.), Sexually transmitted diseases. Raven Press, Ltd., New York, N.Y.
|
| 37.
|
Perry, L. L.,
K. Feilzer, and H. D. Caldwell.
1997.
Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways.
J. Immunol.
158:3344-3352[Abstract].
|
| 38.
|
Perry, L. L.,
K. Feilzer,
J. L. Portis, and H. D. Caldwell.
1998.
Distinct homing pathways direct T lymphocytes to the genital and intestinal mucosae in Chlamydia-infected mice.
J. Immunol.
160:2905-2914[Abstract/Free Full Text].
|
| 39.
|
Sampaio, S. O.,
X. Li,
M. Takeuchi,
C. Mei,
U. Francke,
E. C. Butcher, and M. J. Briskin.
1995.
Organization, regulatory sequences, and alternatively spliced transcripts of the mucosal addressin cell adhesion molecule-1 (MAdCAM-1) gene.
J. Immunol.
155:2477-2486[Abstract].
|
| 40.
|
Springer, T. A.
1994.
Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm.
Cell
76:301-314[CrossRef][Medline].
|
| 41.
|
Steffen, B. J.,
G. Breier,
E. C. Butcher,
M. Schulz, and B. Engelhardt.
1996.
ICAM-1, VCAM-1, and MAdCAM-1 are expressed on choroid plexus epithelium but not endothelium and mediate binding of lymphocytes in vitro.
Am. J. Pathol.
148:1819-1838[Abstract].
|
| 42.
|
Streeter, P. R.,
E. L. Berg,
B. T. Rouse,
R. F. Bargatze, and E. C. Butcher.
1988.
A tissue-specific endothelial cell molecule involved in lymphocyte homing.
Nature
331:41-46[CrossRef][Medline].
|
| 43.
|
Su, H.,
K. Feilzer,
H. D. Caldwell, and R. P. Morrison.
1997.
Chlamydia trachomatis genital tract infection of antibody-deficient gene knockout mice.
Infect. Immun.
65:1993-1999[Abstract].
|
| 44.
|
Taylor, H. R.,
S. L. Johnson,
R. A. Prendergast,
J. Schachter,
C. R. Dawson, and A. M. Silverstein.
1982.
An animal model of trachoma. II. The importance of repeated reinfection.
Investig. Ophthalmol. Vis. Sci.
23:507-515[Abstract/Free Full Text].
|
| 45.
|
VanCott, J. L.,
H. F. Staats,
D. W. Pascual,
M. Roberts,
S. N. Chatfield,
M. Yamamoto,
M. Coste,
P. B. Carter,
H. Kiyono, and J. R. McGhee.
1996.
Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages and derived cytokines following oral immunization with live recombinant Salmonella.
J. Immunol.
156:1504-1514[Abstract].
|
| 46.
|
Whittum-Hudson, J. A.,
L. L. Ann,
W. M. Saltzman,
R. A. Prendergast, and A. B. MacDonald.
1996.
Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection.
Nat. Med.
2:1116-1121[CrossRef][Medline].
|
| 47.
|
Whittum-Hudson, J. A.,
T. P. O'Brien, and R. A. Prendergast.
1995.
Murine model of ocular infection by a human biovar of Chlamydia trachomatis.
Investig. Ophthalmol. Vis. Sci.
36:1976-1987[Abstract/Free Full Text].
|
| 48.
|
Williams, D. M.,
B. G. Grubbs,
E. Pack,
K. Kelly, and R. G. Rank.
1997.
Humoral and cellular immunity in secondary infection due to murine Chlamydia trachomatis.
Infect. Immun.
65:2876-2882[Abstract].
|
| 49.
|
Wu, H.-Y., and M. W. Russell.
1997.
Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system.
Immunol. Res.
16:187-201[Medline].
|
| 50.
|
Yang, X., and R. C. Brunham.
1998.
Gene knockout B cell-deficient mice demonstrate that B cells play an important role in the initiation of T cell responses to Chlamydia trachomatis (mouse pneumonitis) lung infection.
J. Immunol.
161:1439-1446[Abstract/Free Full Text].
|
| 51.
|
Yang, X., and R. C. Brunham.
1998.
Role of T cell-mediated immunity in host defense against Chlamydia trachomatis and its implication for vaccine development.
Can. J. Infect. Dis.
9:99.
|
| 52.
|
Yang, Y.,
P. M. Cardarelli,
K. Lehnert,
S. Rowland, and G. W. Krissansen.
1998.
LPAM-1(integrin alpha 4 beta 7)-ligand binding: overlapping binding sites recognizing VCAM-1, MAdCAM-1 and CS-1 are blocked by fibrinogen, a fibronectin-like polymer and RGD-like cyclic peptides.
Eur. J. Immunol.
28:995-1004[CrossRef][Medline].
|
| 53.
|
Yang, Y. P.,
S. M. Loosmore,
B. J. Underdown, and M. H. Klein.
1998.
Nasopharyngeal colonization with nontypeable Haemophilus influenzae in chinchillas.
Infect. Immun.
66:1973-1980[Abstract/Free Full Text].
|
Infection and Immunity, March 2001, p. 1832-1840, Vol. 69, No. 3
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.3.1832-1840.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Morrison, R. P., Caldwell, H. D.
(2002). Immunity to Murine Chlamydial Genital Infection. Infect. Immun.
70: 2741-2751
[Full Text]
-
Belay, T., Eko, F. O., Ananaba, G. A., Bowers, S., Moore, T., Lyn, D., Igietseme, J. U.
(2002). Chemokine and Chemokine Receptor Dynamics during Genital Chlamydial Infection. Infect. Immun.
70: 844-850
[Abstract]
[Full Text]